ENANTA PHARMACEUTICALS, INC (ENTA) Free cash flow 2017–2025
ENANTA PHARMACEUTICALS, INC (ENTA) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$32.2MFY2025 · since FY2017: $50.1M → -$32.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$32.2M | +66.7% |
| FY2024 | -$96.7M | +13.8% |
| FY2023 | -$112.2M | -29.1% |
| FY2022 | -$86.9M | -22.8% |
| FY2021 | -$70.7M | -1353.7% |
| FY2020 | $5.6M | -91.5% |
| FY2019 | $66.0M | +151.5% |
| FY2018 | $26.2M | -47.7% |
| FY2017 | $50.1M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ENTA financial trends
ENTA RevenueENTA Net incomeENTA Net marginENTA Gross profitENTA Gross marginENTA Operating incomeENTA Operating marginENTA Operating cash flowENTA Capital expendituresENTA Return on equityENTA Stock buybacksENTA Dividends paidENTA Total assetsENTA Total liabilitiesENTA Shareholders’ equityENTA overview →